Uncategorized
Clearside completes enrollment in phase 2 Tanzanite trial
Enrollment in a phase 2 clinical trial of CLS-TA and Eylea for treatment of macular edema associated with retinal vein occlusion is complete, according to a press release from Clearside Biomedical Inc.The Tanzanite trial is intended to evaluate safety and efficacy of a single injection of CLS-TA (triamcinolone acetonide) delivered via the suprachoroidal space (SCS) combined with an initial intravitreal injection of aflibercept (Eylea, Regeneron).